Weight Loss and Metabolic Peptides

Semaglutide is a GLP-1 receptor agonist primarily used for managing type 2 diabetes and aiding in weight loss. It works by mimicking the GLP-1 hormone, which enhances insulin secretion, reduces glucagon release, and slows gastric emptying, leading to reduced appetite. Available as both a subcutaneous injection and an oral tablet, semaglutide offers flexibility in administration. Its long half-life allows for weekly dosing, making it a convenient option for patients.

Liraglutide is a GLP-1 receptor agonist primarily used for weight management and Type 2 diabetes control. It mimics the action of the GLP-1 hormone, enhancing insulin secretion, inhibiting glucagon release, and slowing gastric emptying. This results in increased satiety and reduced appetite, making it an effective tool for managing weight and blood glucose levels. Approved by the FDA in 2010, it is administered via subcutaneous injection and is known for its favorable safety profile when used as prescribed.

Tirzepatide is a novel dual agonist peptide that targets both the GIP and GLP-1 receptors, offering a unique approach to managing obesity and type 2 diabetes. Its dual mechanism enhances insulin secretion and reduces appetite, leading to significant weight loss and improved glycemic control. Approved in 2021, it has quickly gained attention for its efficacy in metabolic health management.

Exenatide is a synthetic peptide that mimics the incretin hormone GLP-1, primarily used for managing type 2 diabetes and aiding in weight loss. It works by enhancing insulin secretion in response to meals, suppressing glucagon release, and slowing gastric emptying, which helps control blood sugar levels and reduces appetite. Approved by the FDA in 2005, Exenatide has become a valuable tool in the management of metabolic disorders, offering benefits in glycemic control and weight management.

Dulaglutide is a glucagon-like peptide-1 receptor agonist used primarily for the management of type 2 diabetes and as an aid in weight loss. It functions by enhancing insulin secretion, suppressing glucagon release, and slowing gastric emptying, which collectively improve glycemic control and promote weight reduction. Administered via subcutaneous injection, dulaglutide is typically dosed once weekly, offering a convenient option for patients requiring long-term management of their metabolic conditions.

Lixisenatide is a glucagon-like peptide-1 receptor agonist primarily used for managing type 2 diabetes and aiding in weight loss. By mimicking the action of the GLP-1 hormone, it enhances insulin secretion in response to meals, slows gastric emptying, and reduces appetite. This peptide is administered via subcutaneous injection and is typically prescribed to individuals who require additional glycemic control or weight management support.

AOD-9604 is a synthetic peptide fragment derived from human growth hormone, specifically designed to aid in weight loss and obesity management. It functions by stimulating lipolysis and inhibiting lipogenesis, effectively targeting fat cells without impacting blood sugar levels. As a growth hormone fragment, it is distinct from full-length growth hormone and is primarily used for its fat-reducing properties.

Retatrutide is a novel triagonist peptide designed to aid in weight loss and metabolic health. By simultaneously activating GLP-1, GIP, and glucagon receptors, it enhances insulin secretion, reduces appetite, and boosts energy expenditure. This multi-faceted approach makes it a promising candidate for managing obesity, type 2 diabetes, and metabolic syndrome. Currently, it is under investigation and not yet approved for widespread clinical use.

MOTS-c is a mitochondrial-derived peptide that plays a crucial role in regulating metabolic homeostasis. It activates AMP-activated protein kinase (AMPK) and modulates the folate cycle, thereby enhancing mitochondrial function and energy expenditure. Primarily used in weight management and metabolic disorders, MOTS-c is administered via subcutaneous injection and is not yet approved by the FDA. It is popular among biohackers and athletes for its potential to improve energy metabolism and support weight loss.

5-Amino-1MQ is a small molecule inhibitor primarily researched for its potential in weight loss and metabolic enhancement. It functions by inhibiting the enzyme nicotinamide N-methyltransferase (NNMT), which is involved in cellular energy metabolism. By reducing NNMT activity, 5-Amino-1MQ may enhance energy expenditure and promote fat loss, making it a promising candidate for anti-obesity interventions. Despite its potential, it is not approved for human use and is currently available for research purposes only.

Survodutide is a novel peptide designed for weight loss and metabolic improvement, acting as a dual agonist for GLP-1 and glucagon receptors. It enhances insulin secretion and promotes satiety, while also increasing energy expenditure, making it a promising candidate for obesity management and type 2 diabetes control. Despite its potential, Survodutide remains investigational, with ongoing research to establish its long-term efficacy and safety.

Orforglipron is an investigational non-peptide GLP-1 receptor agonist primarily developed for weight loss and type 2 diabetes management. It works by enhancing insulin secretion, inhibiting glucagon release, and promoting satiety, which collectively contribute to its metabolic benefits. As an oral medication, it offers a convenient alternative to injectable GLP-1 receptor agonists, making it a promising candidate for individuals seeking non-invasive treatment options.

Mazdutide is a promising investigational peptide designed for weight loss and metabolic improvement. As a dual agonist for GLP-1 and glucagon receptors, it enhances insulin secretion and reduces appetite, making it a potential treatment for obesity and type 2 diabetes. Administered via subcutaneous injection, Mazdutide is currently under investigation for its efficacy and safety in managing metabolic disorders. Its unique mechanism of action allows for significant weight reduction and improved glucose control, positioning it as a potential game-changer in metabolic health management.

CagriSema is a novel combination of cagrilintide, an amylin analogue, and semaglutide, a GLP-1 receptor agonist, designed to enhance satiety and reduce appetite. This dual-action peptide is primarily used for obesity management and type 2 diabetes control, offering a promising approach to metabolic health. Administered via subcutaneous injection, CagriSema is currently under investigation and has shown potential in clinical trials to significantly aid in weight loss and improve glycemic control.

Pemvidutide is a promising investigational peptide designed for weight loss and metabolic health improvement. As a GLP-1 receptor agonist, it enhances insulin secretion and reduces glucagon levels, making it particularly effective for managing obesity and type 2 diabetes. The peptide also slows gastric emptying, which helps reduce appetite and caloric intake, contributing to its weight loss effects. Pemvidutide is administered via subcutaneous injection, typically on a weekly basis, and has shown potential in clinical trials for significant weight reduction and improved glycemic control.

Adipotide, also known as FTPP, is a chimeric peptide primarily researched for its potential in weight loss and metabolic management. It functions by targeting the blood supply to adipose tissue, leading to the apoptosis of fat cells. This mechanism makes it a promising candidate for obesity treatment, as it directly reduces fat mass by disrupting the vascular support of white adipose tissue. Despite its potential, Adipotide remains a research chemical and is not approved for clinical use.